blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3810116

EP3810116 - NOVEL SUBSTITUTED [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  13.10.2023
Database last updated on 02.09.2024
FormerGrant of patent is intended
Status updated on  30.05.2023
FormerExamination is in progress
Status updated on  09.09.2022
FormerRequest for examination was made
Status updated on  26.03.2021
FormerThe international publication has been made
Status updated on  07.12.2019
Most recent event   Tooltip02.08.2024Lapse of the patent in a contracting state
New state(s): IT, SK		published on 04.09.2024 [2024/36]
Applicant(s)For all designated states
Merck Sharp & Dohme LLC
126 East Lincoln Avenue
Rahway, New Jersey 07065 / US
[2022/42]
Former [2021/17]For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Road
Rahway, New Jersey 07065-0907 / US
Inventor(s)01 / HE, Shuwen
158 Second Street
Fanwood, New Jersey 07023 / US
02 / CLAUSEN, Dane
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
03 / GUO, Liangqin
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
04 / HAN, Yongxin
33 Avenue Louis Pasteur
Boston, Massachusetts 02115-5727 / US
05 / HUANG, Xianhai
16 Hemlock Circle
Warren, New Jersey 07059 / US
06 / PASTERNAK, Alexander
33 Avenue Louis Pasteur
Boston, Massachusetts 02115-5727 / US
07 / PU, Qinglin
33 Avenue Louis Pasteur
Boston, Massachusetts 02115-5727 / US
08 / XIAO, Dong
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
09 / XIAO, Li
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
10 / ZHANG, Hongjun
33 Avenue Louis Pasteur
Boston, Massachusetts 02115-5727 / US
 [2021/17]
Representative(s)Merck Sharp & Dohme LLC
120 Moorgate
London EC2M 6UR / GB
[2023/46]
Former [2021/17]Hussain, Deeba
Merck Sharp & Dohme Corp.
120 Moorgate
London, EC2M 6UR / GB
Application number, filing date19811446.428.05.2019
[2021/17]
WO2019US34088
Priority number, dateUS201862678568P31.05.2018         Original published format: US 201862678568 P
[2021/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019231870
Date:05.12.2019
Language:EN
[2019/49]
Type: A1 Application with search report 
No.:EP3810116
Date:28.04.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 05.12.2019 takes the place of the publication of the European patent application.
[2021/17]
Type: B1 Patent specification 
No.:EP3810116
Date:15.11.2023
Language:EN
[2023/46]
Search report(s)International search report - published on:US05.12.2019
(Supplementary) European search report - dispatched on:EP03.12.2021
ClassificationIPC:C07D237/34, C07D239/42, C07D239/70, C07D239/94, C07D241/20, C07D471/04, C07C237/14, A61K31/166, A61P25/00, A61P31/12, A61P35/00
[2022/01]
CPC:
A61P31/12 (EP); C07C271/14 (US); A61P25/00 (EP);
A61P35/00 (EP,US); C07C237/14 (EP); C07D213/74 (EP,US);
C07D237/34 (EP,US); C07D239/42 (EP,US); C07D239/70 (EP);
C07D239/94 (EP,US); C07D241/20 (EP,US); C07D471/04 (EP,US);
A61K45/06 (US); C07B2200/07 (EP); C07C2602/38 (EP) (-)
Former IPC [2021/17]A61K31/166, C07C13/08, C07C233/65
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/17]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:NEUARTIGE SUBSTITUIERTE [1.1.1]-BICYCLO-VERBINDUNGEN ALS INDOLAMIN-2,3-DIOXYGENASE-INHIBITOREN[2021/17]
English:NOVEL SUBSTITUTED [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS[2021/17]
French:NOUVEAUX COMPOSÉS [1,1,1]BICYCLO SUBSTITUÉS EN TANT QU'INHIBITEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE[2021/17]
Entry into regional phase11.01.2021National basic fee paid 
11.01.2021Search fee paid 
11.01.2021Designation fee(s) paid 
11.01.2021Examination fee paid 
Examination procedure11.01.2021Examination requested  [2021/17]
30.06.2022Amendment by applicant (claims and/or description)
09.09.2022Despatch of a communication from the examining division (Time limit: M06)
20.03.2023Reply to a communication from the examining division
31.05.2023Communication of intention to grant the patent
05.10.2023Fee for grant paid
05.10.2023Fee for publishing/printing paid
05.10.2023Receipt of the translation of the claim(s)
Fees paidRenewal fee
11.05.2021Renewal fee patent year 03
21.03.2022Renewal fee patent year 04
21.03.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT15.11.2023
CZ15.11.2023
DK15.11.2023
EE15.11.2023
ES15.11.2023
HR15.11.2023
IT15.11.2023
LT15.11.2023
LV15.11.2023
NL15.11.2023
PL15.11.2023
RO15.11.2023
RS15.11.2023
SE15.11.2023
SK15.11.2023
SM15.11.2023
BG15.02.2024
NO15.02.2024
GR16.02.2024
IS15.03.2024
PT15.03.2024
[2024/36]
Former [2024/35]AT15.11.2023
CZ15.11.2023
DK15.11.2023
EE15.11.2023
ES15.11.2023
HR15.11.2023
LT15.11.2023
LV15.11.2023
NL15.11.2023
PL15.11.2023
RO15.11.2023
RS15.11.2023
SE15.11.2023
SM15.11.2023
BG15.02.2024
NO15.02.2024
GR16.02.2024
IS15.03.2024
PT15.03.2024
Former [2024/34]AT15.11.2023
DK15.11.2023
EE15.11.2023
ES15.11.2023
HR15.11.2023
LT15.11.2023
LV15.11.2023
NL15.11.2023
PL15.11.2023
RS15.11.2023
SE15.11.2023
SM15.11.2023
BG15.02.2024
NO15.02.2024
GR16.02.2024
IS15.03.2024
PT15.03.2024
Former [2024/33]AT15.11.2023
DK15.11.2023
ES15.11.2023
HR15.11.2023
LT15.11.2023
LV15.11.2023
NL15.11.2023
PL15.11.2023
RS15.11.2023
SE15.11.2023
SM15.11.2023
BG15.02.2024
NO15.02.2024
GR16.02.2024
IS15.03.2024
PT15.03.2024
Former [2024/26]AT15.11.2023
ES15.11.2023
HR15.11.2023
LT15.11.2023
LV15.11.2023
NL15.11.2023
PL15.11.2023
RS15.11.2023
SE15.11.2023
BG15.02.2024
NO15.02.2024
GR16.02.2024
IS15.03.2024
PT15.03.2024
Former [2024/25]AT15.11.2023
ES15.11.2023
HR15.11.2023
LT15.11.2023
NL15.11.2023
PL15.11.2023
RS15.11.2023
SE15.11.2023
BG15.02.2024
NO15.02.2024
GR16.02.2024
IS15.03.2024
PT15.03.2024
Former [2024/23]AT15.11.2023
ES15.11.2023
LT15.11.2023
NL15.11.2023
BG15.02.2024
GR16.02.2024
IS15.03.2024
PT15.03.2024
Former [2024/21]LT15.11.2023
NL15.11.2023
BG15.02.2024
GR16.02.2024
IS15.03.2024
Former [2024/20]GR16.02.2024
IS15.03.2024
Documents cited:Search[A]WO2016165613  (HANGZHOU INNOGATE PHARMA CO LTD [CN]) [A] 1-21 * claims 1,20,27,31 *;
 [E]WO2019204180  (MERCK SHARP & DOHME [US], et al) [E] 1-21 * claims 1,18 *;
 [E]WO2019231871  (MERCK SHARP & DOHME [US], et al) [E] 1-21 * claims 1,16 *;
 [A]  - JAE EUN CHEONG ET AL, "A patent review of IDO1 inhibitors for cancer", EXPERT OPINION ON THERAPEUTIC PATENTS, GB, (20180223), vol. 28, no. 4, doi:10.1080/13543776.2018.1441290, ISSN 1354-3776, pages 317 - 330, XP055544298 [A] 1-21 * page 323; compounds 36-37 *

DOI:   http://dx.doi.org/10.1080/13543776.2018.1441290
International search[A]US2016075654  (BUNKER KEVIN DUANE [US], et al) [A] 1-16, 18 * , entire document, especially: para [0238], formula 21-3. *;
 [A]  - PubChem, (20180129), Database accession no. 132090779 [A] 1-16, 18 * , pg 2, Fig. *
 [A]  - NELP et al., "Immune-modulating enzyme indoleamine-2,3-dioxygenase is effectively inhibited by targeting its apo-form", Proceedings of the National Academy of Sciences, (20180327), vol. 115, no. 13, doi:10.1073/pnas.1719190115, ISSN 0027-8424, pages 3249 - 3254, XP055643566 [A] 1-16, 18 * , entire document. *

DOI:   http://dx.doi.org/10.1073/pnas.1719190115
by applicantWO0102369
 WO0210192
 WO02068470
 WO2004004771
 WO2004056875
 WO2004072286
 US7488802
 US7521051
 WO2010027827
 WO2010077634
 WO2011066342
 US8008449
 US2011271358
 US8168757
 US8354509
 WO2013019906
 US8383796
 WO2016165613
 WO2019204180
 WO2019231871
    - DAUBENER et al., Adv. Exp. Med. Biol, (19990000), vol. 467, pages 517 - 24
    - TAYLOR et al., FASEB J., (19910000), vol. 5, pages 2516 - 22
    - LOGAN et al., Immunology, (20020000), vol. 105, pages 478 - 87
    - BROWN et al., Adv. Exp. Med. Biol, (19910000), vol. 294, pages 425 - 35
    - PORTULA et al., Blood, (20050000), vol. 106, pages 2382 - 90
    - MEDAWAR, Symp. Soc. Exp. Biol., (19530000), vol. 7, pages 320 - 38
    - MOAN et al., Science, (19980000), vol. 281, pages 1191 - 3
    - UYTTENHOVE et al., Nature Med., (20030000), vol. 9, pages 1269 - 74
    - MULLER et al., Nature Med., (20050000), vol. 11, pages 312 - 9
    - MUNN et al., Science, (20020000), vol. 297, pages 1867 - 70
    - MUNN et al., J. Clin. Invest, (20040000), vol. 114, no. 2, pages 280 - 90
    - GROHMANN et al., Trends Immunol, (20030000), vol. 24, pages 242 - 8
    - WIRLEITNER et al., Curr. Med. Chem., (20030000), vol. 10, pages 1581 - 91
    - "NCBI", the American Pharmaceutical Association and the Pharmaceutical Press, Database accession no. NP_079515
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.